Clinical significance of HLA class I heavy chain expression in patients with gastric cancer
Clinical significance of HLA class I heavy chain expression in patients with gastric cancer
复制标题
DOI：
10.1002/jso.20985
复制
发表时间：
2008-04-01
影响因子：
2.5
通讯作者：
Kitano, Seigo
中科院分区：
文献类型：
--
作者：
Ueda, Yoshitake;Ishikawa, Koichi;Kitano, Seigo
背景：人类白细胞抗原-I类分子的表达与胃癌患者预后的关系尚不清楚。本研究旨在探讨胃癌组织中人类白细胞抗原-I重链表达的临床意义。方法：202例胃癌根治性手术患者为研究对象。用免疫组织化学方法检测肿瘤组织中人类白细胞抗原-I重链抗原的表达。结果：HL A-B/C表达与肿瘤侵袭深度、淋巴结转移率、肿瘤分期和复发率有关。与肿瘤混合表达和阴性表达的患者相比，HLA-B/C阳性表达患者的5年总生存期和5年无瘤生存期较短(P<；0.05和0.01)。在多因素分析中，HLAB/C表达虽未被认为是独立的预后因素，但它是预测胃癌根治术后腹膜复发的独立因素[相对危险度(RR)：9.924，P=0.003]。结论：HLAB/C重链表达与肿瘤进展有关，可作为预测胃癌根治术后腹膜复发的重要指标。
Background: Little is known about the relation between HLA-I expression and the prognosis of patients with gastric cancer. The aim of this retrospective study was to clarify-the clinical significance of HLA-I heavy chain expression in gastric cancer.Methods: The study subjects were 202 patients with gastric cancer who had undergone curative surgery. Tumors were examined for expression of HLA-I heavy chain antigens by immunohistochemistry. We analyzed the association of HLA-I heavy chain expression with clinicopathological parameters and patient prognosis.Results: HLA-B/C expression showed association with deeper tumor invasion, higher incidence of lymph node metastasis, more advanced tumor stage, and higher incidence of recurrence. Patients with positive HLA-B/C expression had shorter 5-year overall and 5-year disease-free survival compared with patients whose tumors showed mixed and negative expression (P < 0.05 and 0.01, respectively). In multivariate analysis, although HLA-B/C expression was not recognized as an independent prognostic factor, it was an independent factor in predicting peritoneal recurrence after curative surgery in patients with gastric cancer [relative risk (RR): 9.924, P = 0.003].Conclusion: Expression of HLA-B/C heavy chain is associated with tumor progression, and it could be a significant predictor of peritoneal recurrence after curative surgery in patients with gastric cancer.